Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67

November 9, 2016 4:04 PM EST

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment